COMPASS Pathways (NASDAQ:CMPS) Earns Buy Rating from Analysts at Stifel Nicolaus

Research analysts at Stifel Nicolaus began coverage on shares of COMPASS Pathways (NASDAQ:CMPS - Get Free Report) in a research report issued to clients and investors on Thursday, Marketbeat reports. The firm set a "buy" rating and a $11.00 price target on the stock. Stifel Nicolaus' target price suggests a potential upside of 179.90% from the company's previous close.

CMPS has been the topic of a number of other research reports. Maxim Group cut their price target on COMPASS Pathways from $22.00 to $12.00 and set a "buy" rating on the stock in a report on Friday, November 1st. HC Wainwright cut their target price on COMPASS Pathways from $60.00 to $45.00 and set a "buy" rating on the stock in a research note on Thursday, February 13th. Finally, Royal Bank of Canada restated an "outperform" rating and set a $18.00 price objective on shares of COMPASS Pathways in a research note on Wednesday, January 15th. Seven research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company currently has a consensus rating of "Buy" and an average price target of $21.83.

COMPASS Pathways Stock Performance

CMPS stock traded up $0.01 during mid-day trading on Thursday, reaching $3.93. The company had a trading volume of 1,247,976 shares, compared to its average volume of 1,273,099. The company has a quick ratio of 8.91, a current ratio of 8.91 and a debt-to-equity ratio of 0.15. The stock has a market capitalization of $268.89 million, a P/E ratio of -1.79 and a beta of 2.28. COMPASS Pathways has a one year low of $3.16 and a one year high of $12.57. The stock's 50-day simple moving average is $4.06 and its two-hundred day simple moving average is $5.24.

Remove Ads

COMPASS Pathways (NASDAQ:CMPS - Get Free Report) last issued its quarterly earnings data on Thursday, February 27th. The company reported ($0.63) earnings per share for the quarter, missing the consensus estimate of ($0.62) by ($0.01). Research analysts anticipate that COMPASS Pathways will post -2.33 EPS for the current year.

Institutional Investors Weigh In On COMPASS Pathways

Hedge funds and other institutional investors have recently bought and sold shares of the business. Polar Asset Management Partners Inc. raised its position in COMPASS Pathways by 83.3% in the third quarter. Polar Asset Management Partners Inc. now owns 567,600 shares of the company's stock worth $3,576,000 after acquiring an additional 258,000 shares in the last quarter. Sio Capital Management LLC raised its holdings in shares of COMPASS Pathways by 211.7% in the 3rd quarter. Sio Capital Management LLC now owns 914,639 shares of the company's stock worth $5,762,000 after purchasing an additional 621,222 shares in the last quarter. Walleye Capital LLC bought a new position in shares of COMPASS Pathways in the third quarter valued at $2,126,000. Geode Capital Management LLC increased its holdings in shares of COMPASS Pathways by 160.3% in the third quarter. Geode Capital Management LLC now owns 42,169 shares of the company's stock valued at $266,000 after buying an additional 25,970 shares in the last quarter. Finally, Acuta Capital Partners LLC bought a new position in shares of COMPASS Pathways in the third quarter valued at $2,435,000. 46.19% of the stock is currently owned by institutional investors.

COMPASS Pathways Company Profile

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.